-
2022-502606-33-00
5
2021-02-26
Patients with histologically or cytologically documented non-squamous
-
2023-507475-21-00
10
2021-01-18
Lung Cancer, Non-Small Cell
-
2024-514502-31-00
5
2021-01-11
Prurigo Nodularis
-
2023-503384-41-00
5
2020-12-22
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2024-514404-13-00
5
2020-10-01
Atopic Dermatitis
-
2023-506576-27-00
5
2020-09-30
EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
-
2023-504998-20-00
5
2020-09-18
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
-
2022-502746-27-00
5
2020-08-21
Endometrial Cancer
-
2023-503591-25-00
5
2020-06-09
Non-small cell lung cancer
-
2024-516680-91-00
5
2020-05-21
relapsing multiple sclerosis
-
2022-501973-37-00
5
2020-01-30
Endometrial cancer
-
2023-505980-36-00
5
2019-09-19
Primary progressive multiple sclerosis (PPMS)
-
2023-505478-14-00
5
2019-05-09
Psoriatic Arthritis
-
2023-509576-42-00
5
2019-02-21
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
-
2023-509602-29-00
5
2019-02-11
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
-
2023-510015-19-00
5
2019-02-11
Patients with histologically or cytologically documented muscle-invasi
-
2023-505495-30-00
5
2019-02-01
Immunoglobulin A Nephropathy (IgAN)
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2024-510605-28-00
5
2018-11-27
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
-
2023-507657-15-00
5
2018-09-13
Ulcerative Colitis
-
2023-506861-76-00
5
2018-08-09
Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplasti
-
2023-504736-18-00
10
2018-07-26
Moderately to Severely Active Crohn's Disease
-
2023-506399-28-00
5
2017-11-08
Crohn's Disease